Clinical Trials Logo

Filter by:
NCT ID: NCT06255171 Recruiting - Suicidal Behaviour Clinical Trials

Social Media and Suicidal Behaviour - Study 1

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

There is limited research investigating the correlation between suicidal behavior in the general population and online journalism reporting on suicide. Even less explored are the roles and characteristics of suicide-related news posts on social media platforms, along with reader comments, and their association with users' experiences. The primary objective of this randomized controlled trial is to experimentally examine the influence of these post features on user perceptions. Participants are expected to be university students or young adults. In line with this aim, the following research question has been posed: How do users of social media and forums perceive news posts about suicide on social media platforms? Participants will complete a screening battery of questionnaires. Those who will be eligible to participate will be divided into 1 experimental and 2 control groups. Firstly the participants will fill out a questionnaire regarding their current mood. Each group will read posts of a different theme, one of them will be suicidal behavior, deaths due to traffic accidents, and nature. They will be asked to observe and read 4 social media posts and their corresponding articles. After each article, they will answer a few questions on how they perceived these articles and how are they currently feeling. After the main part of the study, all groups of participants will be involved in a group debriefing conversation.

NCT ID: NCT06250543 Completed - Overactive Bladder Clinical Trials

Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder

Start date: August 14, 2018
Phase: Phase 4
Study type: Interventional

A randomized, single blind, non-inferiority clinical study was performed evaluating the efficacy and safety of AbobotulinumtoxinA vs. IncobotulinumtoxinA intradetrusor injections in women with overactive bladder and urge urinary incontinence. Also the effect of local anesthesia on pain level of the procedure was assessed.

NCT ID: NCT06216639 Enrolling by invitation - Clinical trials for Helicobacter Pylori Infection

Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection

Start date: February 1, 2024
Phase:
Study type: Observational

This prospective non-interventional study is being conducted as part of the EU4Health project Eurohelican. The main goal of this pilot study is to evaluate the feasibility and acceptability of implementing the proposed "test-and-treat" screening program on a population-based sample. Participants will be randomly selected from a younger population registered at the primary level of care and tested for the presence of active infection with Helicobacter pylori (H. pylori). Infected participants will undergo a bismuth-based quadruple treatment with antibiotics and a proton pump inhibitor, and will be controlled for eradication success by taking the urea breath test (UBT). A number of other participant outcomes will be also measured to provide additional pro et contra argumentation for the potential future implementation of a population-based test-and-treat screening program in Slovenia. Research reports will be disseminated and results will be presented to the public and scientific community to foster future developments in gastric cancer prevention.

NCT ID: NCT06207747 Active, not recruiting - Melanoma Clinical Trials

Quantitative Analysis of PET/CT Images of Immune Related Side Effects in Metastatic Melanoma Patients

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

New cancer treatment with immune-checkpoint inhibitors (ICIs) has changed the way patients with melanoma and a variety of other cancers are being treated. Many pivotal trials that showed efficacy and safety of ICIs were performed in malignant melanoma. ICI can cause a different type of toxicity, called immune-related adverse events (irAEs). Though the exact pathophysiology is not completely understood, it is believed that irAEs are provoked by immune upregulation and inflammation. However, they can be serious, life-threatening, and warrant hospital admission as well. Dangerous irAEs include myocarditis, myositis, and pneumonitis, among others. Due to the novel mechanism of action, unpredictable nature, and wide usage of this type of treatment in the future, there is urgent need for better control of these potentially dangerous side effects. Early recognition and treatment of irAEs are of great importance in successful management. Positron emission tomography-computed tomography (PET/CT) with [18F]2fluoro-2-deoxy-D-glucose (18F-FDG) is a sensitive, non-invasive, and widely used method for diagnosis and evaluation of treatment efficacy of malignant melanoma. The combination of 18F-FDG-PET and CT allows for assessment of both functional and morphological status of the lesions, and so facilitates better clinical decisions and patient care during treatment. It is also a very sensitive method for recognising inflammation, that can be a signal of irAEs. Quantitative analysis is a rapidly evolving field of PET/CT image analysis. It includes both radiomics and artificial intelligence. Some studies have reported that quantitative analysis could predict efficacy of different cancer treatments. Quantitative image analysis in cancer response assessment is a rapidly expanding field, with the ultimate goal of clinical translation. However, in the specific instance of irAE diagnosis, it is not yet clear what role quantitative analysis of PET/CT scans can play. The hypothesis is that quantitative analysis of PET/CT images provides more information on possible irAE, thus helping to treat these side effects more quickly and successfully.

NCT ID: NCT06207500 Terminated - Clinical trials for Medication Reconciliation

Evaluation of Pharmacist-led Medication Reconciliation Service Benefits in Hospitalised Medical Patients

Start date: September 30, 2019
Phase: N/A
Study type: Interventional

Background: Transitions of care often lead to medication errors and unnecessary healthcare utilisation. It has been repeatedly shown that medication reconciliation can at least partially reduce this risk. Objective: The aim of this prospective pragmatic trial was to evaluate the effectiveness of pharmacist-led medication reconciliation offered to medical patients as part of routine clinical practise. The main questions to be answered were: - the effectiveness of pharmacist-led medication reconciliation on medication discrepancies at discharge and 30 days after discharge - the effectiveness of pharmacist-led medication reconciliation on healthcare utilisation within 30 days after discharge. Participants in the intervention group were offered the following: - medication reconciliation on admission - medication reconciliation on discharge, coupled with patient counselling, provided by clinical pharmacists. Participants in the control group were offered standard care.

NCT ID: NCT06174441 Enrolling by invitation - Hair Loss Clinical Trials

The Effect of 24-week Dietary Intake of Food Supplements on Hair

TO-HAIR
Start date: January 8, 2024
Phase: N/A
Study type: Interventional

Purpose of this randomized, double-blind, placebo-controlled study will be to evaluate whether the daily use of novel dietary supplements over 24 weeks is able strengthen and promote growth of hairs, improve their density and thickness and reduce hair loss in adults with self-perceived thinning hair.

NCT ID: NCT06158724 Withdrawn - Covid19 Clinical Trials

COVID-19 Personal Protective Equipment for Vaccinated Health Workers and Convalescents

Start date: March 1, 2021
Phase:
Study type: Observational

The aim of the trial is to assess the safety of using simplified personal protective equipment (PPE) for vaccinated or COVID-19 convalescent healthcare workers working in COVID-19 ICU or COVID-19 wards. The trial is designed as a prospective randomiyed observational trial with volunteer medical staff working in COVID-19 departments aiming to show non-inferiority of simplified PPE vs standard COVID-19 PPE.

NCT ID: NCT06155812 Recruiting - Shock, Septic Clinical Trials

Multimodal Vasopressor Strategy in Septic Shock

Start date: November 3, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this prospective randomized controlled trial is to compare the effects of classic stepwise vs. early balanced multimodal vasopressor strategies in septic shock.

NCT ID: NCT06154044 Recruiting - Heart Failure Clinical Trials

Cell Therapy and Myocardial Recovery in Heart Failure Patients Undergoing Left Ventricular Assist Device Support

CELL-VAD
Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

The goal of CELL-VAD Pilot trial is to investigate a personalized stem cell therapy approach for patients with advanced non-ischemic chronic heart failure (NICM) who are supported by LVAD. In the clinical trial, the investigators aim to enroll 10 patients with NICM, scheduled for LVAD implantation. After successful LVAD implantation, patients will be enrolled and followed for 2 months to allow for postoperative rehabilitation and heart failure medical therapy and LVAD support optimization. All patients will then undergo autologous CD34+ cell therapy which will be intracoronaryly delivered to the target myocardium using NOGA electromechanical mapping system. All patients will be followed for 6 months after cell therapy. At baseline, and at 1, 3, and 6 months after cell therapy, the investigators will perform comprehensive clinical evaluation.

NCT ID: NCT06153160 Recruiting - Cardiac Arrest Clinical Trials

"The Effect of the Use of an Autotransfusion Device on Hemodynamic Parameters During Resuscitation".

Start date: November 22, 2023
Phase: N/A
Study type: Interventional

The purpose of the research (pilot study) is to determine the impact of the use of the autotransfusion device on hemodynamic parameters during resuscitation. 24 people will be included in the pilot study (12 people will be included in the intervention group - with the usage of "autotransfusion socks" during resuscitation and 12 people in the control group - without "autotransfusion socks"). Investigators will compare the hemodynamic parameters and also neurological outcome between both groups.